-
Professor Guosheng Ren & Professor Nicolas Leymarie: Rebuilding Lives, Advancing Together—Reflections and Future Perspectives on Sino-French Breast Reconstruction Collaboration | Sino-French Breast Reconstruction Congress
The 15th Sino-French Breast Reconstruction Congress and the 13th Sino-French Breast Cancer Academic Conference recently concluded successfully in Chongqing. As one of the long-standing academic meetings in the field of breast cancer, this year’s congress brought together leading Chinese and French experts in breast cancer treatment for live surgical demonstrations and in-depth discussions focused on…
-
2026 HOT Conference | Professor Tengfei Chao: Precision Treatment Strategies After Progression on CDK4/6 Inhibitor Plus Endocrine Therapy
From April 16–18, 2026, the 18th Northern Breast Cancer HOT Conference was successfully held in Henan Province. The meeting focused on cutting-edge advances and clinical challenges in breast cancer diagnosis and treatment, bringing together leading Chinese experts to explore new pathways toward standardized and individualized care.
-
ESMO BC 2026 | Academician Binghe Xu and Professor Jiayu Wang: Real-World Use of Adjuvant Abemaciclib in Chinese Patients With HR+/HER2− Early Breast Cancer
Based on the results of the monarchE trial, abemaciclib combined with endocrine therapy (ET) has become the standard adjuvant treatment for patients with high-risk HR+/HER2− early breast cancer (EBC). However, systematic data regarding its use in routine Chinese clinical practice have remained limited.
-
CSCO BC 10th Anniversary Tribute · International Edition | Professor Zefei Jiang in Dialogue With Professor Michael Gnant: From SGBCC to CSCO BC—East-West Collaboration Shaping the Future of Breast Cancer Care
During the 2026 National Breast Cancer Conference, Professor Michael Gnant, President of the St. Gallen International Breast Cancer Conference (SGBCC), traveled across continents to participate in the event, further deepening collaboration between SGBCC and the Breast Cancer Committee of the Chinese Society of Clinical Oncology (CSCO BC).
-
Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types
The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago from May 29 to June 2 (local time). As one of the world’s leading oncology conferences, the ASCO Annual Meeting serves as a key venue for presenting advances in cancer research and clinical development. This year, Hengrui Pharma presented more than…
-
ESMO BC International Perspective | Professor François Clément Bidard: SERENA-6 Screening Data Highlight the Value of Continuous ESR1 Mutation Monitoring to Precisely Intercept Progression in HR+ Advanced Breast Cancer
At the recently concluded ESMO Breast Cancer Congress 2026 (ESMO BC 2026), Professor Matteo Lambertini from IRCCS Ospedale Policlinico San Martino and the University of Genova served as one of the chairs of the session “Breast Cancer in Young Women (BCY) Session – Management of HR+ Breast Cancer in Young Women.” Together with fellow panelists,…
-
ESMO BC International Perspective | Professor François Clément Bidard: SERENA-6 Screening Data Highlight the Value of Continuous ESR1 Mutation Monitoring to Precisely Intercept Progression in HR+ Advanced Breast Cancer
ESR1 mutation is a major mechanism of acquired resistance during first-line endocrine therapy for HR+/HER2− advanced breast cancer. At this year’s ESMO Breast Cancer Congress, Professor François Clément Bidard from Institut Curie presented screening-phase data from the SERENA-6 study (Abstract No. 419RO).
-
ESMO BC Global Perspective | Professor Neelima Vidula: Pembrolizumab Plus Carboplatin Did Not Improve Disease Control in Advanced Breast Cancer With Chest Wall Disease, but the Search for Durable Responses Continues
At the 2026 ESMO Breast Cancer Congress (ESMO BC), Professor Neelima Vidula from Massachusetts General Hospital presented the findings of the randomized phase II ICI-CHEST, TBCRC044 study (Abstract No. 425RO), offering important clinical insights into one of the most challenging settings in advanced breast cancer. The study investigated whether adding the PD-1 inhibitor pembrolizumab to…
Connecting Medical Expertise through Media